|
"There are several possibilities as to what effect stopping HRT has. Possibly, it slows the growth of tumors that are there but aren't big enough yet to be detected on a mammogram. Or it could be removing the hormone fuel stops the growth completely or even causes tumor regression"
|
|
Key Points of this article
|
|
The risk of developing breast cancer from use of these hormones is relatively small
|
|
For some women with postmenopausal symptoms, the benefits of HRT are well worth that risk
|
|
The study is not suggesting that all women stop their use of HRT
|
|
This kind of study can't prove causality
|
|
|
|
|
Main results
|
|
In the published study, the investigators say that plummeting use of HRT in mid-2002, after results of the Women's Health Initiative study were announced, correlated with a steep decline in new breast cancer diagnoses that started shortly thereafter and continued through 2003. Incidence in 2004 leveled maintained the same low level of incidence, the lowest rate seen since about 1987, the researchers say.
|
|
|
Hormone Replacement Therapy
|
Menopause is the time in a woman's life when her period stops. It is a normal part of aging. In the years before and during menopause, the levels of female hormones can go up and down. This can cause symptoms such as hot flashes and vaginal dryness. Some women take hormone replacement therapy (HRT) to relieve these symptoms. HRT may also protect against osteoporosis.
However, HRT also has risks. It can increase your risk of breast cancer, heart disease and stroke. Certain types of HRT have a higher risk, and each woman's own risks can vary depending upon her health history and lifestyle. You and your health care provider need to discuss the risks and benefits for you. If you do decide to take HRT, it should be the lowest dose that helps and for the shortest time needed. Taking hormones should be re-evaluated every six months. Source: National Heart, Lung, and Blood Institute
|
|
By The University of Texas M. D. Anderson Cancer Center,
[RxPG] An extended analysis of cancer rates reinforces a strong association between use of hormone replacement therapy (HRT) and increased breast cancer incidence, according to new research. The decline occurred primarily in women age 50-69, the researchers find, and was predominantly seen in estrogen-receptor(ER)-positive cancer - the type of tumors is fueled by estrogen, a hormone that is supplemented in HRT. Such cancers declined 14.7 percent in this time period, compared to a non-significant decline of 1.7 percent in ER-negative tumors.
"For our new data set, 2004, the drop in breast cancer incidence leveled off and remained low in that year, "showing that the decreased rates seen in 2003 were also present in 2004, meaning that the decline was not a one-year wonder, a short-lived anomaly," says Ravdin, the study's lead investigator.
"This kind of study can't prove causality, but the data present a very compelling link between hormone replacement therapy and breast cancer," says Berry, the study's senior investigator.
Using data derived from National Cancer Institute (NCI) cancer registries that report on 9 percent of the U.S. population, they found that the total decrease in breast cancer incidence was 6.7 percent between 2002 and 2003. They also calculated that by the end of 2002, about 20 million fewer prescriptions for HRT were written in the United States- a decrease of 38 percent. Interest in HRT use dropped after the 16,608-participant federal Women's Health Initiative study results were announced in July 2002 and showed that the risks of taking these agents outweighed the benefits for many post-menopausal women.
Ravdin and Berry strongly stress, however, that their study is not suggesting that all women stop their use of HRT.
"This study is not saying that an individual woman will reduce her absolute risk of developing breast cancer by 15 percent by immediately discontinuing use of HRT," Berry says.
While it may be true that stopping use of HRT may have prevented as many as 14,000 breast cancers in 2003 compared with 2002, the percentage of decline is based on an entire population, he explains. "At best, based on this analysis, an individual woman could reduce her individual risk of developing breast cancer by one in 60, or about 1.7 percent, if she stopped using hormones," Berry says.
As a physician, Ravdin tells his patients to follow currently accepted guidelines for HRT use: to use the drug at the lowest dose and for the shortest time period to control hot flashes and other debilitating symptoms caused by the onset of menopause.
"The risk of developing breast cancer from use of these hormones is relatively small and for some women with postmenopausal symptoms, the benefits of HRT are well worth that risk," he says. "This is just another small piece of the puzzle to help women gauge the risks and benefits of using HRT."
The researchers also say that their study cannot answer three key questions: whether stopping the use of HRT leads to a permanent or a temporary decline in breast cancer incidence; if this effect is seen for stopping all types of HRT; and how much of a contributing role other factors may have played in the decline.
"There are several possibilities as to what effect stopping HRT has. Possibly, it slows the growth of tumors that are there but aren't big enough yet to be detected on a mammogram. Or it could be removing the hormone fuel stops the growth completely or even causes tumor regression," Berry says. "We don't know which is correct."
While Berry, an expert in statistics, adds that he was initially surprised that stopping HRT use could have such an immediate impact on breast cancer growth, Ravdin, the clinician, says he was not.
"We know that if you treat ER-positive breast cancer with anti-hormone treatment, you can see shrinkage within weeks, so why wouldn't withdrawing hormones have the same kind of effect on smaller cancers that have not yet been detected?" says Ravdin. "My thought is that these tumors don't completely disappear, but they have stopped growing - hopefully, for many of them, forever."
As to the impact of other factors on breast cancer decline, the researchers say that one contributing factor could be declining use of mammography by women who have stopped using HRT. NCI data has reported a 3.2 percent decline in screening mammography in 2003 for women 50-65 years old, compared to 2000, Berry says, but adds, "such a change would seem insufficient to explain the decline in breast cancer incidence." A large drop in screening would have been seen in breast tumors that are both ER-positive and ER-negative, and that wasn't the case.
Finally, the researchers say that this study may lead to new insights into both the etiology of breast cancer and its prevention. "We will continue modeling incidence rates to try to understand whether what we are seeing is a slowing or a regressing of tumors, or a mix between these two things," Berry says.
The study was funded by grants from the National Cancer Institute and from M. D. Anderson. Co-authors also include Kathy Cronin, Ph.D., Nadia Howlander, M.S., Christine Berg, M.D., Eric Feuer, Ph.D., and Brenda Edwards, Ph.D., from the National Cancer Institute, and Rowan Chlebowski, M.D., Ph.D., from Harbor UCLA Medical Center. 04/18/07
Original research article:
http://content.nejm.org/cgi/reprint/356/16/1670.pdf 
Publication:
Ravdin, Peter M., Cronin, Kathleen A., Howlader, Nadia, Berg, Christine D., Chlebowski, Rowan T., Feuer, Eric J., Edwards, Brenda K., Berry, Donald A.; The Decrease in Breast-Cancer Incidence in 2003 in the United States; N Engl J Med 2007 356: 1670-1674
On the web:
www.mdanderson.org
|
| Funding information and declaration of competing interests:
The study was funded by grants from the National Cancer Institute and from M. D. Anderson. No potential conflict of interest relevant to this article was reported.
|
Advertise in this space for $10 per month.
Contact us today.
|
 |
|
Subscribe to Breast Cancer Newsletter
|
|
|
|
About Dr. Venkat Yelamanchili
|
This news story has been reviewed by Dr. Venkat Yelamanchili before its publication on RxPG News website. Dr. Venkata Yelamanchili , MBBS is a editor of RxPG News. In his capacity as the editor, he is responsible for content related to latest research news in psychiatry. His areas of special interest are General Psychiatry and Therapeutic communities.
RxPG News is committed to promotion and implementation of Evidence Based Medical Journalism in all channels of mass media including internet.
|
|
Additional information about the news article
|
The research was led by scientists at The University of Texas M. D. Anderson Cancer Center. M. D. Anderson's Peter Ravdin M.D., Ph.D., professor in the Department of Biostatistics, and Donald Berry, Ph.D., head of the Division of Quantitative Sciences, presented the first analysis of the 2002-2003 falling breast cancer rates at the December 2006 meeting of the San Antonio Breast Cancer Symposium. They have since examined breast cancer incidence in 2004. Co-authors also include Kathy Cronin, Ph.D., Nadia Howlander, M.S., Christine Berg, M.D., Eric Feuer, Ph.D., and Brenda Edwards, Ph.D., from the National Cancer Institute, and Rowan Chlebowski, M.D., Ph.D., from Harbor UCLA Medical Center. 04/18/07
|
|
Feedback
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
|
Top of Page
|
